Peer-reviewed veterinary case report
Blood test ratios can predict severity of mitral valve disease in dogs
By Ku, Dayoung et al.·Published in American journal of veterinary research·2023·College of Veterinary Medicine, South Korea·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Severity of myxomatous mitral valve disease in dogs may be predicted using neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratio.
- Species:
- dog
Plain-English summary
A group of dogs with myxomatous mitral valve disease (MMVD), a common heart issue, had their blood tested to see if certain blood cell ratios could predict the severity of their condition. The study found that dogs with more advanced MMVD had higher neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios compared to healthy dogs. After treatment for congestive heart failure, these ratios decreased, indicating improvement. This information can help veterinarians assess heart disease severity and monitor treatment effectiveness in dogs.
People also search for: dog heart disease symptoms · myxomatous mitral valve disease treatment · dog blood test results explained
Abstract
OBJECTIVE: To investigate the neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and platelet-to-lymphocyte ratio (PLR) in dogs with myxomatous mitral valve disease (MMVD). ANIMALS: 106 dogs with MMVD and 22 healthy dogs were included in the study. PROCEDURES: CBC data were obtained retrospectively, and NLR, MLR, and PLR were compared between dogs with MMVD and healthy dogs. The ratios were also analyzed according to MMVD severity. RESULTS: NLR and MLR were significantly higher in dogs with MMVD C and D (NLR of 4.99 [3.69-7.27]; MLR of 0.56 [0.36-0.74]) than in healthy dogs (NLR: 3.05 [1.82-3.37], P < .001; MLR: 0.21 [0.14-0.32], P < .001), MMVD stage B1 (NLR: 3.15 [2.15-3.86], P < .001; MLR: 0.26 [0.20-0.36], P < .001), and MMVD stage B2 dogs (NLR: 3.22 [2.45-3.85], P < .001; MLR: 0.30 [0.19-0.37], P < .001). The area under the receiver operating characteristic curves of the NLR and MLR to distinguish dogs with MMVD C and D from those with MMVD B were 0.84 and 0.89, respectively. The optimal cutoff value for NLR was 4.296 (sensitivity, 68%; specificity, 83.95%), and the MLR value was 0.322 (sensitivity, 96%; specificity, 66.67%). NLR and MLR were significantly decreased after treatment in dogs with congestive heart failure (CHF). CLINICAL RELEVANCE: NLR and MLR can be used as adjunctive indicators of CHF in dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/37024099/